Page last updated: 2024-10-22

tyrphostin ag 1024 and Liver Neoplasms

tyrphostin ag 1024 has been researched along with Liver Neoplasms in 1 studies

tyrphostin AG 1024: modulates radiosensitivity in human breast cancer cells; also an IGF1 receptor inhibitor

Liver Neoplasms: Tumors or cancer of the LIVER.

Research Excerpts

ExcerptRelevanceReference
"In contrast, p53 mutated Huh-7 hepatocellular cancer cells proved to be less sensitive towards cetuximab, but when combined with TKIs or fluvastatin or doxorubicin a pronounced reduction of cell growth was observed."1.33EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. ( Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2005)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Huether, A1
Höpfner, M1
Baradari, V1
Schuppan, D1
Scherübl, H1

Other Studies

1 other study available for tyrphostin ag 1024 and Liver Neoplasms

ArticleYear
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
    Biochemical pharmacology, 2005, Nov-25, Volume: 70, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Cy

2005